Artiva Biotherapeutics Inc
ARTV2.880USD
+0.500+21.01%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
70.25MValor de mercado
PerdaP/L TTM
Mais detalhes de Artiva Biotherapeutics Inc Empresa
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The Company's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Informações da empresa
Código da empresaARTV
Nome da EmpresaArtiva Biotherapeutics Inc
Data de listagemJul 19, 2024
CEODr. Fred Aslan, M.D.
Número de funcionários89
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 19
Endereço5505 Morehouse Drive
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92121
Telefone18582674467
Sitehttps://www.artivabio.com/
Código da empresaARTV
Data de listagemJul 19, 2024
CEODr. Fred Aslan, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
40.97K
-3.85%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-35.76%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
40.97K
-3.85%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-35.76%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RA Capital Management, LP
40.34%
GC Biopharma Corp
18.70%
5AM Ventures
9.63%
VR Adviser, LLC
6.59%
VenBio Partners LLC
4.70%
Outro
20.03%
Investidores
Investidores
Proporção
RA Capital Management, LP
40.34%
GC Biopharma Corp
18.70%
5AM Ventures
9.63%
VR Adviser, LLC
6.59%
VenBio Partners LLC
4.70%
Outro
20.03%
Tipos de investidores
Investidores
Proporção
Venture Capital
57.76%
Corporation
18.70%
Private Equity
4.70%
Investment Advisor/Hedge Fund
4.51%
Hedge Fund
4.08%
Investment Advisor
4.06%
Individual Investor
1.15%
Research Firm
0.82%
Outro
4.21%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
104
25.61M
104.85%
+2.90M
2025Q1
101
26.68M
109.52%
+4.03M
2024Q4
89
26.90M
110.75%
+5.25M
2024Q3
74
26.42M
108.79%
+10.37M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
9.85M
40.44%
--
--
Mar 31, 2025
GC Biopharma Corp
4.57M
18.75%
+4.57M
--
Jul 22, 2024
5AM Ventures
2.35M
9.66%
--
--
Mar 31, 2025
VR Adviser, LLC
1.61M
6.61%
--
--
Mar 31, 2025
VenBio Partners LLC
1.20M
4.92%
-321.00K
-21.12%
Mar 31, 2025
Franklin Advisers, Inc.
520.33K
2.14%
+26.00
+0.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.16M
4.74%
+189.32K
+19.60%
Mar 31, 2025
Samsara BioCapital, LLC
291.67K
1.2%
--
--
Mar 31, 2025
Woodline Partners LP
283.12K
1.16%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
